Sarcoma  >>  rilotumumab (AMG 102)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rilotumumab (AMG 102) / Amgen
NCT01113398: AMG 102 and Avastin for Recurrent Malignant Glioma

Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2
36
US
AMG 102, rilotumumab, Avastin, Bevacizumab
Katy Peters, Amgen
Glioblastoma Multiforme, Gliosarcoma
11/14
09/15
NCT00788957 / 2008-001751-21: Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Checkmark ASCO-GI 2015
Jan 2015 - Jan 2015: ASCO-GI 2015
Checkmark P1/2 data
Jun 2011 - Jun 2011: P1/2 data
Completed
1b/2
153
US, Canada, RoW
Panitumumab, Vectibix®, Ganitumab, AMG 479, Rilotumumab, AMG 102, Placebo
Amgen
Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer, Metastatic Colorectal Cancer, Rectal Cancer
02/12
10/13

Download Options